Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

MRVI Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 148M shares rose 2.6% year over year, in line with the +2.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.6% toward the trailing-twelve-month pace of +2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
148M+1.1% QoQ
Last fiscal yearDec 2025
145.07M+5.2% YoY
LTMJun 2026
146.04M+2.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.6%——
1 year+5.2%——
3-year CAGR+3.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
145.07M USD
Year-over-year change
+5.2%
4-year CAGR
+6.0%

Weighted Avg Shares vs competitors

How MRVI compares with its peers on the latest reported figures

  • MRVI's LTM Jun 2026 weighted avg shares of 146.04M shares is the 5th highest of the 9 companies compared; the peer median is 106.25M shares.
  • Its year-over-year change of +2.7% is the 3rd highest of 9, against a peer median of +0.4%.
  • Over three fiscal years its annual growth of +3.3% compares with a peer median of +2.2%.
MRVI Competitors Peer median
Weighted Avg Shares for MRVI and competitors
Company Period LTM YoY 3-year CAGR
LABStandard BioTools Inc.LTM Mar 2026384.09M +2.7%+69.5%
PACBPacific Biosciences of California, Inc.LTM Mar 2026302.18M +7.4%+10.1%
NEOGNeogen CorporationLTM Aug 2026217.73M +0.3%+4.8%
TECHBio-Techne CorporationLTM Sep 2026156.12M -0.3%-0.3%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026146.04M +2.7%+3.3%
RGENRepligen CorporationLTM Jun 202656.37M +0.5%+0.5%
BLFSBioLife Solutions, Inc.LTM Mar 202647.98M +3.2%+4.0%
AZTAAzenta, Inc.LTM Sep 202645.14M -1.3%-12.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 202626.9M -3.2%-2.9%
Peer median (excluding MRVI) 106.25M+0.4%+2.2%

Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue799.24M883M288.95M259.19M185.74M
Cost of Revenue140.56M168.96M148.74M150.88M152.35M
Gross Profit658.68M714.04M140.2M108.31M33.39M
Gross Margin82.4%80.9%48.5%41.8%18.0%
Research & Development15.22M18.37M17.28M19.22M23.33M
Selling, General & Admin100.06M129.26M151.39M161.77M171.47M
Operating Expenses104.03M139.83M171.85M343.93M40.13M
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
EBITDA585.78M609.99M712.41M(156.92M)(147.51M)
EBITDA Margin73.3%69.1%246.6%-60.5%-79.4%
Operating Income554.65M574.22M(31.65M)(235.62M)(6.74M)
Operating Margin69.4%65.0%-11.0%-90.9%-3.6%
Interest Income02.34M27.73M27.4M23.95M
Interest Expense30.26M20.41M45.89M47.7M26.99M
Other Income / Expenses(23.88M)(22.74M)649.38M(25.87M)(228.24M)
Income Before Tax530.77M551.47M617.74M(261.48M)(234.97M)
Pre-Tax Margin66.4%62.5%213.8%-100.9%-126.5%
Income Tax Expense61.52M60.81M756.11M(1.86M)(4.21M)
Net Income182.04M220.21M(119.03M)(144.85M)(130.77M)
Net Margin22.8%24.9%-41.2%-55.9%-70.4%
EPS (Basic)1.591.67(0.90)(1.05)(0.91)
EPS (Diluted)1.561.67(0.90)(1.05)(0.91)
Weighted Avg Shares114.79M131.54M131.92M137.91M145.07M
Weighted Avg Shares (Diluted)121.97M131.7M131.92M137.91M145.07M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Intrinsic Alpha fair value

Locked

Current Price

$7.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.